Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
9.73
+0.27 (2.85%)
Aug 25, 2026, 1:57 PM EDT - Market open
Atara Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6.19 | 120.77 | 128.94 | 8.57 | 63.57 | 20.34 | |
Revenue Growth | -96.72% | -6.33% | 1404.02% | -86.52% | 212.55% | - |
Cost of Revenue | 1.53 | 46.15 | 155.28 | 228.05 | 269.99 | 282 |
Gross Profit | 4.66 | 74.62 | -26.34 | -219.48 | -206.42 | -261.66 |
Selling, General & Admin | 12.99 | 22.29 | 38.53 | 49.8 | 68.13 | 78.8 |
Research & Development | 2.86 | 2.86 | 13.47 | - | - | - |
Operating Expenses | 15.85 | 25.15 | 51.99 | 49.8 | 68.13 | 78.8 |
Operating Income | -11.19 | 49.47 | -78.33 | -269.28 | -274.55 | -340.46 |
Interest Expense | -2.82 | -3.79 | -4.62 | -5.29 | -0.37 | - |
Interest & Investment Income | 0.44 | 0.68 | 2.11 | 5.43 | 3.06 | 2.14 |
Other Non Operating Income (Expenses) | -0.05 | -0.03 | 0.53 | -0.25 | -0.7 | - |
EBT Excluding Unusual Items | -13.62 | 46.33 | -80.31 | -269.38 | -272.56 | -338.33 |
Merger & Restructuring Charges | -3.04 | -13.61 | -5.11 | -6.73 | -5.96 | - |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -1.77 |
Gain (Loss) on Sale of Assets | - | - | - | - | 50.24 | - |
Pretax Income | -16.66 | 32.72 | -85.42 | -276.11 | -228.29 | -340.1 |
Income Tax Expense | 0.03 | 0.03 | -0.01 | 0.02 | 0.01 | 0.05 |
Net Income | -16.69 | 32.69 | -85.4 | -276.13 | -228.3 | -340.14 |
Net Income to Common | -16.69 | 32.69 | -85.4 | -276.13 | -228.3 | -340.14 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 14 | 13 | 7 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 14 | 13 | 7 | 4 | 4 | 4 |
Shares Change | 36.26% | 69.84% | 76.77% | 3.83% | 8.88% | 26.63% |
EPS (Basic) | -1.19 | 2.61 | -11.41 | -65.19 | -55.96 | -90.78 |
EPS (Diluted) | -1.19 | 2.57 | -11.41 | -65.19 | -55.96 | -90.78 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -21.9 | -50.94 | -68.96 | -194.2 | -274.62 | -231.1 |
Free Cash Flow Per Share | -1.55 | -4.00 | -9.21 | -45.84 | -67.32 | -61.68 |
Gross Margin | 75.27% | 61.79% | -20.43% | - | - | - |
Operating Margin | -180.59% | 40.96% | -60.75% | -3140.98% | -431.86% | -1673.85% |
Profit Margin | -269.42% | 27.07% | -66.23% | -3220.88% | -359.12% | -1672.28% |
Free Cash Flow Margin | -353.49% | -42.18% | -53.49% | -2265.25% | -431.98% | -1136.19% |
EBITDA | -11.06 | 51.59 | -73.28 | -264.45 | -268.9 | -331.12 |
EBITDA Margin | -178.53% | 42.71% | -56.83% | - | - | - |
D&A For EBITDA | 0.13 | 2.12 | 5.05 | 4.83 | 5.65 | 9.35 |
EBIT | -11.19 | 49.47 | -78.33 | -269.28 | -274.55 | -340.46 |
EBIT Margin | -180.59% | 40.96% | -60.75% | - | - | - |
Effective Tax Rate | - | 0.10% | - | - | - | - |
Revenue as Reported | 120.77 | 120.77 | 128.94 | 8.57 | 63.57 | - |